{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:12:20Z","timestamp":1768889540413,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,12,25]],"date-time":"2013-12-25T00:00:00Z","timestamp":1387929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00392-013-0649-z","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T12:20:32Z","timestamp":1387887632000},"page":"505-513","source":"Crossref","is-referenced-by-count":28,"title":["Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials"],"prefix":"10.1007","volume":"103","author":[{"given":"Simona","family":"Silvetti","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Greco","sequence":"additional","affiliation":[]},{"given":"Ambra Licia","family":"Di Prima","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Mucchetti","sequence":"additional","affiliation":[]},{"given":"Castro Maria","family":"de Lurdes","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Pasin","sequence":"additional","affiliation":[]},{"given":"Mara","family":"Scandroglio","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Landoni","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Zangrillo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,12,25]]},"reference":[{"key":"649_CR1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","volume":"9","author":"M Metra","year":"2007","unstructured":"Metra M, Ponikoswki P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, B\u00f6hm M, Anker S, Dargie H, Brutsaert D, Komajda M, for the Heart FailureAssociation of the European Society of Cardiology (2007) Advanced chronic heart failure: a positionstatement from the Study Group on Advanced Heart Failure of the Heart Failure Association ofthe European Society of Cardiology. Eur J Heart Fail 9:684\u2013694","journal-title":"Eur J Heart Fail"},{"key":"649_CR2","doi-asserted-by":"crossref","first-page":"47G","DOI":"10.1016\/j.amjcard.2005.07.021","volume":"96","author":"M Bayram","year":"2005","unstructured":"Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96:47G\u201358G","journal-title":"Am J Cardiol"},{"key":"649_CR3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","volume":"4","author":"S Thackray","year":"2002","unstructured":"Thackray S, Easthaugh J, Freemantle N, Cleland JG (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4:515\u2013529","journal-title":"Eur J Heart Fail"},{"key":"649_CR4","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","volume":"30","author":"M Metra","year":"2009","unstructured":"Metra M, Eichhorn E, Abraham WT, Linseman J, B\u00f6hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR, ESSENTIAL Investigators (2009) Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: The randomized, doubleblind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 30:3015\u20133026","journal-title":"Eur Heart J"},{"key":"649_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","volume":"46","author":"WT Abraham","year":"2005","unstructured":"Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J, ADHERE Scientific Advisory Committee and Investigators, ADHERE Study Group (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46:57\u201364","journal-title":"J Am Coll Cardiol"},{"key":"649_CR6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","volume":"37","author":"A Mebazaa","year":"2011","unstructured":"Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37:290\u2013301","journal-title":"Intensive Care Med"},{"key":"649_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0733-8651(18)30126-7","volume":"12","author":"K Chatterjee","year":"1994","unstructured":"Chatterjee K, Wolfe CL, De Marco T (1994) Nonglycoside inotropes in congestive heart failure: are they beneficial or harmful? Cardiol Clin 12:63\u201372","journal-title":"Cardiol Clin"},{"key":"649_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.RES.0000054624.03539.B4","volume":"92","author":"A Remondino","year":"2003","unstructured":"Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, Colucci WS (2003) Beta-adrenergic receptor stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species\/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136\u2013138","journal-title":"Circ Res"},{"key":"649_CR9","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, The PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468\u20131475","journal-title":"N Engl J Med"},{"key":"649_CR10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Str\u00f6mberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG) (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933\u2013989","journal-title":"Eur J Heart Fail"},{"key":"649_CR11","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIRCULATIONAHA.109.192065","volume":"119","author":"SA Hunt","year":"2009","unstructured":"Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:e391\u2013e479","journal-title":"Circulation"},{"key":"649_CR12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14779072.5.3.571","volume":"5","author":"SG Drakos","year":"2007","unstructured":"Drakos SG, Charitos EI, Nanas SN, Nanas JN (2007) Ventricular-assist devices for the treatment of chronic heart failure. Expert Rev Cardiovasc Ther 5:571\u2013584","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"649_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2003.12.006","volume":"486","author":"T Sorsa","year":"2004","unstructured":"Sorsa T, Pollesello P, Rosevear PR, Drakenberg T, Kilpel\u00e4inen I (2004) Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol 486:1\u20138","journal-title":"Eur J Pharmacol"},{"key":"649_CR14","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1074\/jbc.M007484200","volume":"276","author":"T Sorsa","year":"2001","unstructured":"Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I (2001) Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276:9337\u20139343","journal-title":"J Biol Chem"},{"key":"649_CR15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejheart.2005.02.002","volume":"7","author":"C Avgeropoulou","year":"2005","unstructured":"Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I (2005) The Ca(2+)-sensitizer levosimendan improves oxidative damage, BNP and proinflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7:882\u2013887","journal-title":"Eur J Heart Fail"},{"key":"649_CR16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"VS Moiseyev","year":"2002","unstructured":"Moiseyev VS, P\u00f5der P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI, RUSSLAN Study Investigators (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J 23:1422\u20131432","journal-title":"Eur Heart J"},{"key":"649_CR17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196\u2013202","journal-title":"Lancet"},{"key":"649_CR18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","volume":"40","author":"G Landoni","year":"2012","unstructured":"Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A (2012) Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 40:634\u2013646","journal-title":"Crit Care Med"},{"key":"649_CR19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ije\/dyh311","volume":"34","author":"GG Biondi-Zoccai","year":"2005","unstructured":"Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F (2005) A simple hint to improve Robinson and Dickersin\u2019s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 34:224\u2013225","journal-title":"Int J Epidemiol"},{"key":"649_CR20","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. http:\/\/www.cochranehandbook.org . Accessed March 2011"},{"key":"649_CR21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"649_CR22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"issue":"3","key":"649_CR23","first-page":"161","volume":"3","author":"G Biondi-Zoccai","year":"2011","unstructured":"Biondi-Zoccai G, Lotrionte M, Landoni G, Modena MG (2011) The rough guide to systematic reviews and meta-analyses. HSR Proc Intensive Care Cardiovas Anesth 3(3):161\u2013173","journal-title":"HSR Proc Intensive Care Cardiovas Anesth"},{"key":"649_CR24","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"649_CR25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejheart.2008.09.006","volume":"10","author":"MS Nieminen","year":"2008","unstructured":"Nieminen MS, Cleland JGF, Eha J, Belenkov Y, Kivikko M, P\u00f5der P, Sarapohja T (2008) Oral levosimendan in patients with severe chronic heart failure\u2014the PERSIST study. Eur J Heart Fail 10:1246\u20131254","journal-title":"Eur J Heart Fail"},{"key":"649_CR26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5414\/CPP46389","volume":"8","author":"VP Harjola","year":"2008","unstructured":"Harjola VP, Oikarinen L, Toivonen L, Jurkko R, Puttonen J, Sarapohja T, Sundberg S, Nieminen MS (2008) The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA classes II\u2013III heart failure. Int J Clin Pharmacol Ther 8:389\u2013399","journal-title":"Int J Clin Pharmacol Ther"},{"key":"649_CR27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0091270004268319","volume":"44","author":"P P\u00f5der","year":"2004","unstructured":"P\u00f5der P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L (2004) Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 44:1143\u20131150","journal-title":"J Clin Pharmacol"},{"key":"649_CR28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2004.11.033","volume":"95","author":"JN Nanas","year":"2005","unstructured":"Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, Kanakakis J, Nanas SN, Alexopoulos GP, Anastasiou-Nana MI (2005) Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 95:768\u2013771","journal-title":"Am J Cardiol"},{"key":"649_CR29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.hlc.2007.10.014","volume":"17","author":"NM Parle","year":"2008","unstructured":"Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO (2008) Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure\u2014a single-centre experience. Heart Lung Circ 17:206\u2013210","journal-title":"Heart Lung Circ"},{"key":"649_CR30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00392-013-0554-5","volume":"102","author":"PO Tuomainen","year":"2013","unstructured":"Tuomainen PO, Magga J, Timonen P, Miettinen K, Kurttila M, Vanninen E, Laitinen T, Timonen K, Punnonen K, Parviainen I, Uusaro A, Vuolteenaho O, Kivikko M, Peuhkurinen K (2013) Intermittent levosimendan treatment in patients with severe congestive heart failure. Clin Res Cardiol 102:485\u2013493","journal-title":"Clin Res Cardiol"},{"key":"649_CR31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14017431.2011.557779","volume":"45","author":"M Jalanko","year":"2011","unstructured":"Jalanko M, Kivikko M, Harjola VP, Nieminen MS, Laine M (2011) Oral levosimendan improves filling pressure and systolic function during long-term treatment. Scand Cardiovasc J 45:91\u201397","journal-title":"Scand Cardiovasc J"},{"key":"649_CR32","unstructured":"Bonios M, Terrovitis J, Drakos J, Pozios I, Tseliou E, Katsaros L, Kaldara E, Alexopoulos G, Kanakakis J, Nanas J (2010) Intermittent inotropic infusions for the treatment of refractory end stage heart failure: a randomized clinical study. Abstract presented at ESC Congress 2010"},{"key":"649_CR33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/eurjhf\/hfp189","volume":"12","author":"J Altenberger","year":"2010","unstructured":"Altenberger J, Parissis JT, Ulmer H, Poelzl G, Levo Rep Investigators (2010) Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in out patients with advanced heart failure (Levo Rep Study). Eur J Heart Fail 12:186\u2013192","journal-title":"Eur J Heart Fail"},{"key":"649_CR34","first-page":"555","volume":"92","author":"YH Zhang","year":"2012","unstructured":"Zhang YH, Qing EM, Zhang J, Huang Y, L\u00fc R, Zhou Q, Wei BQ, An T, Qing P, Zou CH (2012) Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure. Zhonghua Yi Xue Za Zhi. 92:555\u2013558","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"649_CR35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0091270008325150","volume":"49","author":"FX Kleber","year":"2009","unstructured":"Kleber FX, Bollmann T, Borst MM, Costard-J\u00e4ckle A, Ewert R, Kivikko M, Petterson T, Pohjanjousi P, Sonntag S, Wikstr\u00f6m G (2009) Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 49:109\u2013115","journal-title":"J Clin Pharmacol"},{"key":"649_CR36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejheart.2006.06.001","volume":"9","author":"R Berger","year":"2007","unstructured":"Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, Pacher R (2007) Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 9:202\u2013208","journal-title":"Eur J Heart Fail"},{"key":"649_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2011.03.013","volume":"159","author":"MJ Bonios","year":"2012","unstructured":"Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, Kanakakis J, Alexopoulos G, Toumanidis S, Anastasiou-Nana M, Nanas JN (2012) Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 159:225\u2013229","journal-title":"Int J Cardiol"},{"key":"649_CR38","doi-asserted-by":"crossref","first-page":"S865","DOI":"10.1161\/CIRCULATIONAHA.108.814533","volume":"120","author":"R Levin","year":"2009","unstructured":"Levin R, Porcile R, Tanus E, Degrange M (2009) Abstract 3815: the intermittent infusion of levosimendan reduces mortality and re-admissions in patients with advanced heart failure. Circulation 120:S865","journal-title":"Circulation"},{"key":"649_CR39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","volume":"60","author":"G Malfatto","year":"2012","unstructured":"Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, Parati G (2012) Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance and one-year survival. J Cardiovasc Pharmacol 60:450\u2013455","journal-title":"J Cardiovasc Pharmacol"},{"key":"649_CR40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","volume":"13","author":"S Mavrogeni","year":"2007","unstructured":"Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, Cokkinos DV (2007) 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 13:556\u2013559","journal-title":"J Card Fail"},{"key":"649_CR41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1136\/hrt.2006.079707","volume":"92","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT (2006) Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92:1768\u20131772","journal-title":"Heart"},{"key":"649_CR42","first-page":"276","volume":"76","author":"G Landoni","year":"2010","unstructured":"Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P, Ajello V, Marino G, Guarracino F, Zangrillo A (2010) Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 76:276\u2013286","journal-title":"Minerva Anestesiol"},{"key":"649_CR43","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, P\u00f5der P, Kivikko M, SURVIVE Investigators (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883\u20131891","journal-title":"JAMA"},{"key":"649_CR44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","volume":"11","author":"A Mebazaa","year":"2009","unstructured":"Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A (2009) Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 11:304\u2013311","journal-title":"Eur J Heart Fail"},{"key":"649_CR45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijcard.2004.02.013","volume":"99","author":"S Kyrzopoulos","year":"2005","unstructured":"Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E, Degiannis D, Kremastinos DT (2005) Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99:409\u2013413","journal-title":"Int J Cardiol"},{"key":"649_CR46","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/sj.bjp.0706781","volume":"148","author":"N Erdei","year":"2006","unstructured":"Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z (2006) The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. Br J Pharmacol 148:696\u2013702","journal-title":"Br J Pharmacol"},{"key":"649_CR47","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B\u00f6hm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, K\u00f8ber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, R\u00f8nnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803\u201369"},{"key":"649_CR48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, \u00c9des I, Fruhwald S, De Hert SG, Salmenper\u00e4 M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikstr\u00f6m BG, J\u00f6rgensen K, Filippatos G, Parissis JT, Gonz\u00e1lez MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159:82\u201387","journal-title":"Int J Cardiol"},{"key":"649_CR49","author":"DT Majure","year":"2012","unstructured":"Majure DT, Greco T, Greco M, Ponschab M, Biondi-Zoccai G, Zangrillo A, Landoni G (2012) Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: an update. J Cardiothorac Vasc Anesth. doi: 10.1053\/j.jvca.2012.08.005","journal-title":"J Cardiothorac Vasc Anesth"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-013-0649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-013-0649-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-013-0649-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T09:24:03Z","timestamp":1564997043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-013-0649-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,25]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1007\/s00392-013-0649-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,25]]}}}